Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Capital Expenditures for 18 consecutive years, with $168.0 million the latest figure, recorded in Q1 2026.

• Quarterly Capital Expenditures rose 32.28% year-over-year to $168.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $542.0 million (up 8.18% YoY) and the FY2025 annual result came in at $501.0 million, up 0.6% from the prior year.
• Capital Expenditures improved to $168.0 million in Q1 2026 per TEVA's latest filing, from $142.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for TEVA reached as high as $168.0 million in Q1 2026 and fell as low as $96.0 million in Q2 2025.
• A 5-year average of $131.8 million and a median of $129.0 million in 2024 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2024 — Capital Expenditures retreated 18.49% — and 2026, when it jumped 32.28%.
• Year by year, Capital Expenditures stood at $142.0 million in 2022, then slipped by 16.2% to $119.0 million in 2023, then gained by 8.4% to $129.0 million in 2024, then rose by 10.08% to $142.0 million in 2025, then increased by 18.31% to $168.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $168.0 million, $142.0 million, and $136.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.